Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (311-320 of 441) with videos related to

Pageof 45
Sort By:
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Journal of Cannabis Research|June 11, 2022
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohortTangui Barré, Fabrice Carrat, Clémence Ramier, et al.
Journal of Hepatology|August 20, 2014
PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitisDavid Saadoun, Matthieu Resche Rigon, Stanislas Pol, et al.
Journal of Hepatology|August 18, 2020
Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related deathMathieu Chalouni, Stanislas Pol, Philippe Sogni, et al.
Plos One|March 21, 2014
Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infectionSimone Bocchetta, Patrick Maillard, Mami Yamamoto, et al.
Journal of Hepatology|September 2, 2017
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorderVincent Mallet, Julie Bruneau, Julien Zuber, et al.
Journal of Viral Hepatitis|May 22, 2020
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohortVictor de Lédinghen, Clovis Lusivika-Nzinga, Jean-Pierre Bronowicki, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE studyThomas Berg, Pietro Andreone, Stanislas Pol, et al.
Nature Immunology|February 20, 2019
Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growthClémence Hollande, Jeremy Boussier, James Ziai, et al.
Annals of the Rheumatic Diseases|November 15, 2015
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC studyDavid Saadoun, Vincent Thibault, Si Nafa Si Ahmed, et al.
Pageof 45

Showing results (311-320 of 441) with videos related to

Sort By:
Pageof 45
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Journal of Cannabis Research|June 11, 2022
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohortTangui Barré, Fabrice Carrat, Clémence Ramier, et al.
Journal of Hepatology|August 20, 2014
PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitisDavid Saadoun, Matthieu Resche Rigon, Stanislas Pol, et al.
Journal of Hepatology|August 18, 2020
Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related deathMathieu Chalouni, Stanislas Pol, Philippe Sogni, et al.
Plos One|March 21, 2014
Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infectionSimone Bocchetta, Patrick Maillard, Mami Yamamoto, et al.
Journal of Hepatology|September 2, 2017
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorderVincent Mallet, Julie Bruneau, Julien Zuber, et al.
Journal of Viral Hepatitis|May 22, 2020
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohortVictor de Lédinghen, Clovis Lusivika-Nzinga, Jean-Pierre Bronowicki, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE studyThomas Berg, Pietro Andreone, Stanislas Pol, et al.
Nature Immunology|February 20, 2019
Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growthClémence Hollande, Jeremy Boussier, James Ziai, et al.
Annals of the Rheumatic Diseases|November 15, 2015
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC studyDavid Saadoun, Vincent Thibault, Si Nafa Si Ahmed, et al.
Pageof 45